Daily 10 mg rivaroxaban as a therapy for ventricular thrombus related to left ventricular non-compaction cardiomyopathy: A case report

• Published in: Medicine (Baltimore) 2018-01, Vol.97 (4), p.e9670-e9670
• Main Authors: Sun, Huan, Zhao, Qini, Wang, Yanjing, Lakin, Robert, Feng, Haiyan, Fan, Xingyu, Luo, Huiling, Gao, Dongmei, Liu, Lin, He, Yuquan, Yang, Ping
• Format: Article
• Language: English
• Subjects: Adult; Clinical Case Report; Factor Xa Inhibitors - administration & dosage; Humans; Isolated Noncompaction of the Ventricular Myocardium - complications; Male; Rivaroxaban - administration & dosage; Thrombosis - drug therapy; Thrombosis - etiology; Ventricular Dysfunction, Left - drug therapy; Ventricular Dysfunction, Left - etiology
• ISSN: 0025-7974; 1536-5964
• DOI: 10.1097/MD.0000000000009670

Left ventricular non-compaction cardiomyopathy (LVNC) is a rare heart disorder related to thrombosis. Anticoagulant therapy is suggested for the treatment of this disease. The success of the novel oral anticoagulant rivaroxaban as a treatment option for this disorder is unclear. A 43-year-old man who felt dizzy at rest was found to have an intraventricular thrombus. The thrombus was confirmed by echocardiography. And LVNC was diagnosed by cardiac magnetic resonance (CMR) and echocardiography. He was prescribed a low dose (10 mg daily) of rivaroxaban as treatment. After 3 months, the thrombus diminished, and the manifestation disappeared. Low dose of rivaroxaban may serve as a viable option for anticoagulation therapy in LVNC patients, with large clinical trials needed to determine the best course of treatment.